1. Show article details.

    Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit

    PR Newswire – 7:00 AM ET 12/03/2021

    NEWARK, Calif.

  2. Show article details.

    BRIEF-Protagonist Therapeutics Announces The Selection Of Oral Peptide PN-235 Into Phase 2 Clinical Development Program For Multiple Indications

    Reuters – 4:10 PM ET 12/02/2021

    Protagonist Therapeutics Inc (PTGX): * PROTAGONIST THERAPEUTICS ANNOUNCES THE SELECTION OF ORAL PEPTIDE PN-235 INTO PHASE 2 CLINICAL DEVELOPMENT PROGRAM FOR MULTIPLE INDICATIONS. * Protagonist Therapeutics Inc (PTGX) - PN-235 NOW EXPECTED TO ADVANCE INTO MULTIPLE PHASE 2 CLINICAL STUDIES IN 2022.

  3. Show article details.

    Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications

    PR Newswire – 4:05 PM ET 12/02/2021

    NEWARK, Calif.

  4. Show article details.

    BRIEF-Protagonist Therapeutics Announces Positive Phase 2A Data Supporting Use Of Rusfertide As Hereditary Hemochromatosis Therapy

    Reuters – 7:18 AM ET 11/15/2021

    Protagonist Therapeutics Inc (PTGX): * PROTAGONIST THERAPEUTICS ANNOUNCES POSITIVE PHASE 2A DATA SUPPORTING POTENTIAL USE OF RUSFERTIDE AS A FIRST-IN-CLASS THERAPY IN HEREDITARY HEMOCHROMATOSIS. * Protagonist Therapeutics Inc (PTGX) - RUSFERTIDE WAS WELL TOLERATED IN THIS STUDY POPULATION Source text for Eikon: Further company coverage:

  5. Show article details.

    Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis

    PR Newswire – 7:00 AM ET 11/15/2021

    NEWARK, Calif. Kris V. Kowdley, M.D., Director of Liver Institute Northwest, Professor at the Elson S. Floyd College of Medicine at Washington State University, an author of the ACG Guidelines for HH, and the study's principal investigator.

  6. Show article details.

    Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

    PR Newswire – 7:00 AM ET 11/11/2021

    NEWARK, Calif.

  7. Show article details.

    Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting

    PR Newswire – 7:00 AM ET 11/04/2021

    NEWARK, Calif. "We are delighted to have the opportunity to present further evidence of rusfertide's potential to improve outcomes in polycythemia vera and other diseases related to iron dysregulation," said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist.

  8. Show article details.

    BRIEF-Protagonist Therapeutics Q3 Loss Per Share $0.70

    Reuters – 6:39 PM ET 11/03/2021

    Protagonist Therapeutics Inc (PTGX): * PROTAGONIST THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q3 LOSS PER SHARE $0.70. * RESUMPTION OF PHASE 2 STUDY OF RUSFERTIDE IN POLYCYTHEMIA VERA NOW UNDERWAY. * PN-235 MOVES INTO A PSORIASIS INDICATION, PHASE 2 STUDY INITIATION PLANNED FOR EARLY 2022.

  9. Show article details.

    Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    PR Newswire – 4:05 PM ET 11/03/2021

    NEWARK, Calif.

  10. Show article details.

    BRIEF-Protagonist Therapeutics Earns $7.5 Mln Milestone Payment From IL-23 Receptor Collaboration With Janssen

    Reuters – 8:24 AM ET 10/26/2021

    Protagonist Therapeutics Inc (PTGX): * PROTAGONIST THERAPEUTICS EARNS $7.5 MILLION MILESTONE PAYMENT FROM IL-23 RECEPTOR COLLABORATION WITH JANSSEN Source text for Eikon: Further company coverage:

  11. Show article details.

    Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen

    PR Newswire – 7:00 AM ET 10/26/2021

    NEWARK, Calif. "The completion of these Phase 1 activities reflects our continued strength of execution as our collaboration of four-plus years, encompassing three assets in parallel development for multiple indications, continues to make steady progress," said Dinesh Patel, PhD, President and Chief Executive Officer at Protagonist.

  12. Show article details.

    Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

    PR Newswire – 7:00 AM ET 10/12/2021

    NEWARK, Calif.

  13. Show article details.

    BRIEF-Protagonist Therapeutics Announces Removal Of FDA Clinical Hold On Rusfertide Clinical Development Program

    Reuters – 7:40 AM ET 10/11/2021

    Protagonist Therapeutics Inc (PTGX): * PROTAGONIST THERAPEUTICS ANNOUNCES REMOVAL OF FDA CLINICAL HOLD ON RUSFERTIDE CLINICAL DEVELOPMENT PROGRAM. * PROTAGONIST THERAPEUTICS (PTGX) - ALL ONGOING CLINICAL TRIALS OF RUSFERTIDE TO RESUME DOSING. * PROTAGONIST THERAPEUTICS (PTGX) - PHASE 3 REGISTRATIONAL TRIAL PLANNED TO COMMENCE IN Q1 OF 2022 Source text for Eikon: Further company coverage:

  14. Show article details.

    Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program

    PR Newswire – 7:00 AM ET 10/11/2021

    NEWARK, Calif. The Company provided the FDA with all requested information as the basis for a Complete Response and subsequent removal of the clinical hold. The clinical hold was initially triggered by a recent non-clinical finding in a 26-week rasH2 transgenic mouse model indicating benign and malignant subcutaneous skin tumors.

  15. Show article details.

    BRIEF-Protagonist Therapeutics Inc Announces Data From Phase 2 Rusfertide Study In Hereditary Hemochromatosis Selected For Annual AASLD Meeting

    Reuters – 7:20 AM ET 10/04/2021

    Protagonist Therapeutics Inc (PTGX): * PROTAGONIST THERAPEUTICS ANNOUNCES DATA FROM PHASE 2 RUSFERTIDE STUDY IN HEREDITARY HEMOCHROMATOSIS SELECTED FOR ORAL PRESENTATION AT THE ANNUAL AASLD MEETING Source text for Eikon: Further company coverage:

  16. Show article details.

    Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting

    PR Newswire – 7:00 AM ET 10/04/2021

    NEWARK, Calif. "We are pleased to have this opportunity to share new data on rusfertide that establishes clinical proof-of-concept in hereditary hemochromatosis," said Dinesh Patel, Ph.D., President and Chief Executive Officer of Protagonist.

  17. Show article details.

    PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm

    Business Wire – 9:11 PM ET 09/22/2021

    Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. (PTGX) on behalf of Protagonist stockholders. Click here to participate in the action.

  18. Show article details.

    Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) Investors

    GlobeNewswire – 11:40 AM ET 09/22/2021

    The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Protagonist Therapeutics (PTGX), Inc..   Protagonist Therapeutics (PTGX) is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from its proprietary technology pl...

  19. Show article details.

    BRIEF-Protagonist Therapeutics Reports FDA Clinical Hold On Rusfertide Clinical Development Program

    Reuters – 7:14 AM ET 09/17/2021

    Protagonist Therapeutics Inc (PTGX): * PROTAGONIST THERAPEUTICS REPORTS FDA CLINICAL HOLD ON RUSFERTIDE CLINICAL DEVELOPMENT PROGRAM Source text for Eikon: Further company coverage:

  20. Show article details.

    Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program

    PR Newswire – 7:00 AM ET 09/17/2021

    NEWARK, Calif. The clinical hold follows Protagonist's notification to the FDA of a recent non-clinical finding in a 26-week rasH2 transgenic mouse model study. The Company is working with the FDA and will be prepared to make all appropriate updates to clinical study documents and determine the next steps in consultation with the FDA.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    03

    PTGX announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.